• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新泽西州早期浸润性乳腺癌拉丁裔/西班牙裔女性的 Oncotype DX 测试收据:一项基于登记的研究。

Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.

机构信息

Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90032, USA.

Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.

出版信息

Int J Environ Res Public Health. 2021 May 12;18(10):5116. doi: 10.3390/ijerph18105116.

DOI:10.3390/ijerph18105116
PMID:34065945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8151910/
Abstract

Oncotype DX (ODX) is a valid test of breast cancer (BC) recurrence risk and chemotherapy benefit. The purpose of this study was to examine prevalence of and factors associated with receipt of ODX testing among eligible Latinas/Hispanics diagnosed with BC. Sociodemographic and tumor data of BC cases diagnosed between 2008 and 2017 among Latina/Hispanic women ( = 5777) were from the New Jersey State Cancer Registry (NJSCR). Eligibility for ODX testing were based on National Comprehensive Cancer Network guidelines. Multivariable logistic regression models of ODX receipt among eligible women were used to estimate adjusted odds ratios (AOR) and 95% confidence intervals (CI) by demographic and clinicopathologic factors. One-third of Latinas/Hispanics diagnosed with BC were eligible for ODX testing. Among the eligible, 60.9% received ODX testing. Older age (AOR 0.08, 95% CI: 0.04, 0.14), low area-level SES (AOR 0.58, 95% CI: 0.42, 0.52), and being uninsured (AOR 0.58, 95% CI: 0.39, 0.86) were associated with lower odds of ODX testing. While there was relatively high ODX testing among eligible Latina/Hispanic women with BC in New Jersey, our findings suggest that age, insurance status, and area-level SES contribute to unequal access to genetic testing in this group, which might impact BC outcomes.

摘要

Oncotype DX(ODX)是一种有效的乳腺癌(BC)复发风险和化疗获益的检测方法。本研究的目的是检查在新泽西州被诊断为 BC 的合格拉丁裔/西班牙裔女性中,接受 ODX 检测的流行率和相关因素。2008 年至 2017 年间诊断为 BC 的拉丁裔/西班牙裔女性(n=5777)的社会人口统计学和肿瘤数据来自新泽西州癌症登记处(NJSCR)。ODX 检测的合格标准基于国家综合癌症网络指南。使用多变量逻辑回归模型来估计合格女性中 ODX 接受情况的调整优势比(AOR)和 95%置信区间(CI),按人口统计学和临床病理因素进行分层。三分之一的被诊断为 BC 的拉丁裔/西班牙裔女性有资格进行 ODX 检测。在合格者中,有 60.9%接受了 ODX 检测。年龄较大(AOR 0.08,95%CI:0.04,0.14)、低地区社会经济地位(AOR 0.58,95%CI:0.42,0.52)和没有保险(AOR 0.58,95%CI:0.39,0.86)与 ODX 检测的可能性较低相关。尽管新泽西州有相当多的合格拉丁裔/西班牙裔 BC 女性接受了 ODX 检测,但我们的研究结果表明,年龄、保险状况和地区社会经济地位是导致该人群中基因检测机会不平等的因素,这可能会影响 BC 的结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/3b57877aacd5/ijerph-18-05116-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/fc0ee5d9315a/ijerph-18-05116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/0daba4e54126/ijerph-18-05116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/cf06a859352f/ijerph-18-05116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/3b57877aacd5/ijerph-18-05116-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/fc0ee5d9315a/ijerph-18-05116-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/0daba4e54126/ijerph-18-05116-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/cf06a859352f/ijerph-18-05116-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf4/8151910/3b57877aacd5/ijerph-18-05116-g004.jpg

相似文献

1
Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.新泽西州早期浸润性乳腺癌拉丁裔/西班牙裔女性的 Oncotype DX 测试收据:一项基于登记的研究。
Int J Environ Res Public Health. 2021 May 12;18(10):5116. doi: 10.3390/ijerph18105116.
2
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.种族差异导致省略 Oncotype DX 检测,但在完成 Oncotype DX 检测结果后,种族差异并不影响接受化疗。
Breast Cancer Res Treat. 2018 Feb;168(1):207-220. doi: 10.1007/s10549-017-4587-8. Epub 2017 Nov 27.
3
Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.在一项全州范围内基于人群的研究中,Oncotype DX 测试接受情况的种族和民族差异。
J Natl Compr Canc Netw. 2017 Mar;15(3):346-354. doi: 10.6004/jnccn.2017.0034.
4
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.利用临床病理数据,通过一种新型列线图可以预测Oncotype DX乳腺癌复发评分。
Breast Cancer Res Treat. 2017 May;163(1):51-61. doi: 10.1007/s10549-017-4170-3. Epub 2017 Feb 27.
5
Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.激素阳性乳腺癌且 Oncotype DX 复发评分 26-30 分和≥31 分的高危患者的继发侵袭性乳腺癌事件。
Oncology. 2021;99(11):699-702. doi: 10.1159/000517843. Epub 2021 Aug 23.
6
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.17 个 SEER 数据库中 2004-2015 年激素受体阳性乳腺癌女性患者 Oncotype DX 使用的趋势和生存获益。
Breast Cancer Res Treat. 2020 Apr;180(2):491-501. doi: 10.1007/s10549-020-05557-x. Epub 2020 Feb 14.
7
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.Oncotype DX复发评分对佐治亚州化疗差异和乳腺癌死亡率的影响
NPJ Breast Cancer. 2019 Sep 26;5:32. doi: 10.1038/s41523-019-0129-3. eCollection 2019.
8
Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.组织学分级和组织学亚型与 Oncotype DX 复发评分的关系:863 例乳腺癌 Oncotype DX 结果的回顾性分析。
Breast Cancer Res Treat. 2018 Feb;168(1):29-34. doi: 10.1007/s10549-017-4619-4. Epub 2017 Dec 11.
9
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.2010-2016 年新罕布什尔州乳腺癌患者 Oncotype DX 和辅助化疗应用的患者和医生相关因素。
BMC Cancer. 2020 Sep 3;20(1):847. doi: 10.1186/s12885-020-07355-6.
10
Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.基于 TAILORx 临床试验结果的列线图更新 - 可以使用临床病理数据预测 Oncotype DX 乳腺癌复发评分。
Breast. 2019 Aug;46:116-125. doi: 10.1016/j.breast.2019.05.006. Epub 2019 May 10.

引用本文的文献

1
Socioeconomic Disparities in Breast Cancer Survival: Examining Potential Mediator Role of Oncotype DX(ODX) Test and Stage at Diagnosis Among HR+/HER2- Breast Cancer Women.乳腺癌生存中的社会经济差异:探究HR+/HER2-型乳腺癌女性中Oncotype DX(ODX)检测及诊断分期的潜在中介作用
Cancers (Basel). 2025 May 28;17(11):1802. doi: 10.3390/cancers17111802.
2
Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.Oncotype DX 风险复发评分与不同种族/族裔的早期乳腺癌总死亡率。
Cancer Epidemiol Biomarkers Prev. 2022 Apr 1;31(4):821-830. doi: 10.1158/1055-9965.EPI-21-0929.

本文引用的文献

1
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.种族/民族与 21 基因复发评分与美国女性乳腺癌特异性死亡率的关联。
JAMA Oncol. 2021 Mar 1;7(3):370-378. doi: 10.1001/jamaoncol.2020.7320.
2
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
2010-2016 年新罕布什尔州乳腺癌患者 Oncotype DX 和辅助化疗应用的患者和医生相关因素。
BMC Cancer. 2020 Sep 3;20(1):847. doi: 10.1186/s12885-020-07355-6.
4
Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.17 个 SEER 数据库中 2004-2015 年激素受体阳性乳腺癌女性患者 Oncotype DX 使用的趋势和生存获益。
Breast Cancer Res Treat. 2020 Apr;180(2):491-501. doi: 10.1007/s10549-020-05557-x. Epub 2020 Feb 14.
5
Breast Cancer Incidence and Mortality by Molecular Subtype: Statewide Age and Racial/Ethnic Disparities in New Jersey.按分子亚型划分的乳腺癌发病率和死亡率:新泽西州全州范围的年龄及种族/族裔差异
Cancer Health Disparities. 2019;3:e1-e17. doi: 10.9777/chd.2019.1012. Epub 2019 Aug 19.
6
Cancer Statistics for Hispanics/Latinos, 2018.2018 年西班牙裔/拉丁裔癌症统计数据。
CA Cancer J Clin. 2018 Nov;68(6):425-445. doi: 10.3322/caac.21494. Epub 2018 Oct 4.
7
21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.21 基因复发评分检测在老年雌激素受体阳性乳腺癌患者中的应用。
J Geriatr Oncol. 2019 Mar;10(2):322-329. doi: 10.1016/j.jgo.2018.07.006. Epub 2018 Aug 6.
8
Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.种族差异导致省略 Oncotype DX 检测,但在完成 Oncotype DX 检测结果后,种族差异并不影响接受化疗。
Breast Cancer Res Treat. 2018 Feb;168(1):207-220. doi: 10.1007/s10549-017-4587-8. Epub 2017 Nov 27.
9
Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.早期乳腺癌女性的个体化治疗:考虑伴随预后检测 OncotypeDX 和 Adjuvant!Online 的辅助化疗的风险组特异性成本效益分析。
BMC Cancer. 2017 Oct 16;17(1):685. doi: 10.1186/s12885-017-3603-z.
10
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.基于21基因检测法治疗的患者的乳腺癌特异性死亡率:一项基于监测、流行病学和最终结果(SEER)数据库的人群研究
NPJ Breast Cancer. 2016 Jun 8;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.